Benefits of denosumab in treating bone metastases
Intended for healthcare professionals
A&S Science Previous     Next

Benefits of denosumab in treating bone metastases

Carole Farrell Nurse clinician, The Christie NHS Foundation Trust, Manchester

While bisphosphonates are widely used to treat bone disease, many patients experience significant problems. Carole Farrell outlines a new therapy, given as a subcutaneous injection, which can be administered in an outpatient clinic

This article discusses normal bone remodelling and explains how this changes when cancer cells invade the bone. Denosumab is a new agent for the treatment of bone metastases that has a different mode of action from the bisphosphonates used traditionally to treat metastatic bone disease. The article goes on to outline the potential benefits of denosumab use for patients, health professionals and service delivery.

Cancer Nursing Practice. 11, 9, 14-18. doi: 10.7748/cnp2012.11.11.9.14.c9406

Correspondence

Carole.farrell@christie.nhs.uk

Conflict of interest

This article was supported by Amgen

Peer review

This article has been subject to double blind peer review

Want to read more?

RCNi-Plus
Already have access? Log in

or

3-month trial offer for £5.25/month

Subscribe today and save 50% on your first three months
RCNi Plus users have full access to the following benefits:
  • Unlimited access to all 10 RCNi Journals
  • RCNi Learning featuring over 175 modules to easily earn CPD time
  • NMC-compliant RCNi Revalidation Portfolio to stay on track with your progress
  • Personalised newsletters tailored to your interests
  • A customisable dashboard with over 200 topics
Subscribe

Alternatively, you can purchase access to this article for the next seven days. Buy now


Are you a student? Our student subscription has content especially for you.
Find out more